PDF(Pubmed)
Abstract：
Recent progress in the treatment of advanced melanoma has led to the improved survival of affected patients. However, novel treatments also lead to considerable and distinct skin toxicity. To further characterize cutaneous adverse events (AE) of systemic treatments, we conducted a single-center retrospective study of biopsy-proven cutaneous adverse events of melanoma treatment over a period of 10 years at the University Hospital of Zurich, Switzerland. In 102 identified patients, 135 individual skin AEs developed. Immune checkpoint blockade (ICB) was causal for 81 skin AEs, and 54 were related to targeted therapies (TT). Recorded types of skin AEs included lichenoid, maculopapular, acneiform, urticarial, panniculitis, folliculitis, psoriasiform, granulomatous, eczematous, and others. The incidence of skin AEs was higher with TT (18.54%) than with ICB (9.64%, p = 0.0029). Most AEs were low-grade, although 19.21% of AEs were common terminology criteria for adverse events (CTCAE) Grades 3 or 4. A large spectrum of skin AEs was documented during treatment of advanced melanoma, and distinct phenotypes were observed, depending on treatment classes. AEs occurred earlier during treatment with TT than with ICB, and distinct types of skin AEs were associated with respective treatment classes. This study comprehensively describes skin AEs occurring during systemic treatment for melanoma at a single center.
摘要：
晚期黑色素瘤治疗的最新进展已导致受影响患者的生存率提高。然而,新的治疗方法也导致相当大和明显的皮肤毒性。为了进一步表征全身治疗的皮肤不良事件（AE），我们进行了一项单中心回顾性研究，研究了10年的活检证实的黑色素瘤治疗皮肤不良事件，瑞士。在102名确定的患者中，135个个体皮肤出现AE。免疫检查点阻断(ICB)是81种皮肤AE的原因，54例与靶向治疗（TT）相关。记录的皮肤AE类型包括苔藓样，斑丘疹,痤疮,荨麻疹,脂膜炎,毛囊炎,psoriasiform,肉芽肿,湿疹，和其他人。TT组(18.54%)皮肤不良事件发生率高于ICB组(9.64%,p=0.0029)。大多数AE是低等级的，尽管19.21%的AE是常见的不良事件术语标准(CTCAE)3级或4级.在晚期黑色素瘤的治疗过程中记录了大量的皮肤AE，观察到不同的表型，取决于治疗等级。TT治疗期间的AE发生时间比ICB更早，和不同类型的皮肤AE与各自的治疗类别相关。这项研究全面描述了在单个中心的黑色素瘤全身治疗期间发生的皮肤AE。
